MyFinsight
Home
Blog
About
Contact
Download
Download image
Net gain
-$38,327K
(32.25%↑ Y/Y)
Net loss from
continuing operations
-$36,935K
(22.07%↑ Y/Y)
Net loss from
discontinued operations, net...
-$1,392K
(84.82%↑ Y/Y)
Loss from continuing
operations before income...
-$36,935K
(22.07%↑ Y/Y)
Net income from
discontinued operations...
-$1,392K
Other income
(expense), net
$1,402K
(649.73%↑ Y/Y)
Toripalimab
$11,803K
(60.63%↑ Y/Y)
Product And Service
Other
$507K
(101.99%↑ Y/Y)
Loss from operations
-$36,151K
(20.43%↑ Y/Y)
Interest expense
$2,186K
(1.67%↑ Y/Y)
Income from operations
-$1,004K
(-117.91%↓ Y/Y)
Gain on sale
transactions, net
-$388K
Net revenue
$12,310K
(61.99%↑ Y/Y)
Total costs and
expenses
$48,461K
(-8.62%↓ Y/Y)
Net revenue
-$899K
(-102.85%↓ Y/Y)
Total costs and
expenses
$105K
(-99.60%↓ Y/Y)
Selling, general and
administrative
$23,104K
(-11.22%↓ Y/Y)
Research and development
$21,543K
(-11.55%↓ Y/Y)
Cost of goods sold
$3,814K
(43.76%↑ Y/Y)
Cost of goods sold
$55K
(-99.72%↓ Y/Y)
Selling, general and
administrative
$50K
(-99.30%↓ Y/Y)
Back
Back
Income Statement
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)
source: myfinsight.com